Cardiomyopeptide

心肌肽素

Report date: 2026/01/27 10:16:53
NME

Base Information

Drug NameCardiomyopeptide
Drug Alias NameCardiomyopeptidin心肌肽开地米丁
ClassificationNatural product/Extract > Animal extract
Mechanisms of ActionCalcium release-activated calcium channel protein 1 inhibitorsAldose reductase inhibitors
TargetsCalcium release-activated calcium channel protein 1Aldose reductase
Therapy Area/IndicationsCardiomyopathies
Global Approved IndicationsCardiomyopathies
Approved Indications in ChinaCardiomyopathies
Original Approved Country/TerritoryMainland China
Original Approved Date2005/11/14
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhen-Ao Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDalian Zhenao Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeC01EB
Related LinksN/A